Central Nervous System

CNS remains among the most active and challenging realms of drug development, focused on significant and growing market opportunities in categories as diverse as Treatment-Resistant Depression and Alzheimer’s Disease. In 2021, we expect data readouts in novel areas such as psilocybin therapeutics and closely watched trials involving anti-amyloid, anti-tau and immune-modulatory therapeutics.

What we’re watching

• 6 Alzheimer’s Disease (AD) trial readouts in 1H21
• The FDA decision on potential approval for aducanumab for Alzheimer’s (1Q21)
• Anti-Tau data
• COMP360 / Psilocybin 2H21 data in Treatment-Resistant Depression (TRD)
• April 3, 2021 PDUFA for ACAD’s pimavanserin in DRP
• Ph2 POC data for SRPT’s Phase 2 Gene Therapy for DMD in 1Q21
• Ph3 MDD WATERFALL Data for SAGE’s zuranolone in 1H21